Natera, Inc. (NASDAQ:NTRA) Shares Sold by Nisa Investment Advisors LLC

Nisa Investment Advisors LLC reduced its stake in Natera, Inc. (NASDAQ:NTRA) by 2.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 23,600 shares of the medical research company’s stock after selling 700 shares during the period. Nisa Investment Advisors LLC’s holdings in Natera were worth $3,736,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Quarry LP boosted its holdings in Natera by 148.4% in the second quarter. Quarry LP now owns 318 shares of the medical research company’s stock valued at $34,000 after purchasing an additional 190 shares in the last quarter. Versant Capital Management Inc boosted its holdings in shares of Natera by 345.8% in the 4th quarter. Versant Capital Management Inc now owns 214 shares of the medical research company’s stock valued at $34,000 after buying an additional 166 shares in the last quarter. Covestor Ltd grew its position in shares of Natera by 34.3% in the 3rd quarter. Covestor Ltd now owns 372 shares of the medical research company’s stock valued at $47,000 after buying an additional 95 shares during the last quarter. GAMMA Investing LLC raised its stake in Natera by 32.7% during the 3rd quarter. GAMMA Investing LLC now owns 430 shares of the medical research company’s stock worth $55,000 after acquiring an additional 106 shares in the last quarter. Finally, True Wealth Design LLC acquired a new stake in Natera during the 3rd quarter worth $57,000. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Natera

In other Natera news, insider Solomon Moshkevich sold 1,196 shares of Natera stock in a transaction dated Monday, October 28th. The shares were sold at an average price of $118.21, for a total transaction of $141,379.16. Following the completion of the transaction, the insider now owns 110,695 shares in the company, valued at approximately $13,085,255.95. The trade was a 1.07 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Gail Boxer Marcus sold 2,212 shares of the company’s stock in a transaction dated Thursday, November 14th. The shares were sold at an average price of $158.53, for a total transaction of $350,668.36. Following the completion of the sale, the director now directly owns 19,386 shares in the company, valued at $3,073,262.58. This trade represents a 10.24 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 249,940 shares of company stock valued at $41,094,664 in the last quarter. 7.60% of the stock is currently owned by corporate insiders.

Natera Trading Down 2.5 %

NASDAQ:NTRA opened at $167.61 on Friday. The stock has a market capitalization of $22.13 billion, a price-to-earnings ratio of -95.23 and a beta of 1.65. Natera, Inc. has a 1 year low of $62.96 and a 1 year high of $183.00. The stock has a fifty day moving average price of $166.20 and a two-hundred day moving average price of $136.25. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.23 and a current ratio of 4.39.

Natera (NASDAQ:NTRA) last announced its quarterly earnings data on Tuesday, November 12th. The medical research company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.57) by $0.31. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The firm had revenue of $439.80 million during the quarter, compared to analysts’ expectations of $361.43 million. During the same quarter last year, the business earned ($0.95) earnings per share. The business’s revenue for the quarter was up 63.9% compared to the same quarter last year. As a group, sell-side analysts anticipate that Natera, Inc. will post -1.56 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

NTRA has been the topic of several research reports. Canaccord Genuity Group raised their price objective on Natera from $165.00 to $180.00 and gave the stock a “buy” rating in a report on Friday, January 3rd. Morgan Stanley boosted their price objective on Natera from $132.00 to $176.00 and gave the company an “overweight” rating in a research note on Thursday, November 14th. Leerink Partners raised their target price on shares of Natera from $140.00 to $150.00 and gave the stock an “outperform” rating in a research report on Thursday, October 17th. Robert W. Baird upped their price target on shares of Natera from $120.00 to $160.00 and gave the company an “outperform” rating in a research report on Wednesday, November 13th. Finally, Barclays started coverage on shares of Natera in a research note on Thursday. They set an “overweight” rating and a $200.00 price target for the company. One research analyst has rated the stock with a sell rating and seventeen have given a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $162.94.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.